Here are the top health news for the day:
‘Tomato fever’ misleading colloquial name for hand, foot and mouth disease
Medical professional has informed that Tomato fever is a misleading colloquial name for hand, foot and mouth Disease. Tomato fever (or tomato flu) is a disease that gets its name because of the red and round blisters it causes, which look like tomatoes.
“Tomato fever is a misleading colloquial name for hand, foot and mouth disease. This is a mild viral illness commonly affecting young children typically below age 10. It is usually caused by a Coxsackie virus,” according to Dr Rajeev Jayadevan, co-chairman of IMA’s National task force on COVID-19 reports ANI.
Madras HC upholds Medical Council order barring doctor from practice for two years for issuing fake certificate
Upholding the Tamil Nadu Medical Council (TNMC) order barring a doctor from medical practice for two years, the Division bench of Madras High Court recently slammed the concerned doctor for his involvement in issuing fake medical certificate.
Using the false medical certificate, the property of the deceased patient had been transferred to one of the relative’s name depriving the rights of the daughter of the deceased.
For more details check out the link given below:
NMC releases FAQs based on queries raised by foreign medical graduates from Ukraine, China
Based on queries raised by Foreign Medical Students from Ukraine and China, the National Medical Commission (NMC) has released the Frequently Asked Questions (FAQs) for FMGs.
Medical Dialogues had earlier reported that bringing major relief to foreign medicos hit by the COVID-19 pandemic and Russia-Ukraine war, the National Medical Commission (NMC) decided to frame a scheme and granted relaxation to medical graduates who completed their MBBS course from a foreign medical institute without undergoing physical clinical training.
For more details, check out the link given below:
NMC releases FAQs based on queries raised by foreign medical graduates from Ukraine, China
CDSCO approves AstraZeneca Anticancer drug Trastuzumab Deruxtecan Protocol Amendment
Based on the justification provided by the pharma major AstraZeneca, the Subject Expert Committee(SEC) functional under Central Drug Standard Control Organization(CDSCO) has approved the protocol amendment proposal for anticancer drug Trastuzumab Deruxtecan (T-DXd), which is an antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
This came after the firm presented justification/rationale vis-a-vis patient safety for the proposed protocol Amendment version 3.0 dated 23-Nov-2021 to the protocol no. D967C00001 before the committee.
For more details, check out the link given below:
CDSCO Approves AstraZeneca Anticancer Drug Trastuzumab Deruxtecan Protocol Amendment
